Cassava to Pay $40 Million to SEC Over Alzheimer’s Drug Claims
WEB7 hours ago · SAVAW. (Bloomberg) -- Drugmaker Cassava Sciences Inc. and two former executives agreed to pay more than $40 million to resolve US Securities and Exchange Commission claims they misled the public ...
Cassava to Pay $40 Million to SEC Over Alzheimer’s Drug Claims
WEB6 hours ago · September 26, 2024 at 7:11PM EDT. (Bloomberg) -- Drugmaker Cassava Sciences Inc. and two former executives agreed to pay more than $40 million to resolve US Securities and Exchange Commission claims they misled the public about the success of an Alzheimer’s drug trial. Cassava published results in …
SEC Announces $40 Mln Settlement With Cassava ... - Markets …
WEB3 hours ago · Without admitting or denying the allegations, Cassava, Barbier, and Burns consented to civil injunctions against future violations and agreed to pay civil penalties of $40 million, $175,000, and ...
Cassava Sciences Resolves SEC Investigation - Yahoo Finance
WEB9 hours ago · Advertisement. AUSTIN, Texas, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (“Cassava” or the “Company”) (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s ...
Cassava Sciences Resolves SEC Investigation
WEB1 day ago · AUSTIN, Texas, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (“Cassava” or the “Company”) (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, today announced that it has reached a settlement with the U.S. Securities and Exchange Commission (“SEC”) of negligence-based disclosure charges that resolve a previously-disclosed SEC investigation into ...
SEC Charges Cassava Sciences, Two Former Executives for …
WEB1 day ago · The Securities and Exchange Commission today announced Cassava Sciences, Inc., its founder and former CEO, Remi Barbier, and its former Senior Vice President of Neuroscience, Dr. Lindsay Burns, will pay more than $40 million to settle charges related to misleading statements made in September 2020 about the results of a Phase 2 clinical trial for the company’s purported therapeutic for the ...
Cassava Sciences shares fall after SEC charges for misleading …
WEB9 hours ago · The SEC said Cassava will pay $40 million to settle the civil charges, while Remi Barbier, the company's founder and former CEO, and Lindsay Burns, its former senior vice president of neuroscience ...
Cassava Sciences and former execs agree to SEC fines | STAT
WEB7 hours ago · Cassava was charged Thursday by the SEC with making misleading claims in 2020 about trials for its Alzheimer's drug, and agreed to pay fines. ... The news comes on the same day that the SEC filed ...
Alzheimer’s Drug Developer Cassava Paying $40 Million to Settle ...
WEB7 hours ago · Photo: Evan Vucci/Associated Press. Alzheimer’s drug developer Cassava Sciences agreed Thursday to pay $40 million to settle regulatory claims that it misled investors about the results of a ...
Cassava Sciences, Inc. (SAVA) Latest Stock News & Headlines
WEBGet the latest Cassava Sciences, Inc. (SAVA) stock news and headlines to help you in your trading and investing decisions.
Skip to content